Neurological abnormalities specialist Wave Neuroscience said on Thursday that it has closed the brain treatment technology asset purchase agreement with Newport Brain Research Laboratory (NBRL) for an undisclosed amount.
Under the terms of the agreement, Wave Neuroscience purchased substantially all of the assets from the various onshore and offshore holding companies under NBRL.
In conjunction with the acquisition, key NBRL personnel were appointed to new roles at Wave Neuroscience.
Since June, Wave Neuroscience has pledged more than USD500,000 of free treatments to US military members.
According to Wave Neuroscience, its research revolves around the premise that the brain can be treated by non-pharmaceutical and non-surgical means. It offers a personalised treatment platform for addressing neurological abnormalities and has treated more than 7,000 patients using its patented, non-invasive, drug-free MeRT process, which is licensed by a network of independently owned medical facilities.
Mabtech partners with Sai Life Sciences to expand access to EYRA multiplex immunology platform
Mirecule expands collaboration with Sanofi to advance FSHD therapy
Sanofi's venglustat receives FDA Breakthrough Therapy designation for type 3 Gaucher disease
Alebund Pharmaceuticals signs licensing and equity agreements with R1 Therapeutics
Apertura Gene Therapy agrees manufacturing collaboration with Viralgen
Humacyte submits Israel MAA for Symvess arterial trauma repair
Sentynl Therapeutics and PRG S&T enter licensing agreement for potential HGPS treatment
NeuroSense Therapeutics reports Phase 2b trial results of PrimeC in ALS
Avacta opens Phase 1 trial for AVA6103 cancer therapy in US
Imfinzi approved in EU for perioperative treatment of early gastric and gastroesophageal cancers
LynxKite Technologies expands Biophytis collaboration
BioDlink named 'Emerging CDMO of the Year' at Asia-Pacific Biopharma Excellence Awards